ALSO NOTED: Adolor shares rise on NDA news; Indevus plans Phase III; Exelixis earns milestone; and much more...

> Shares of Adolor surged on the news that the FDA's Gastrointestinal Drugs Advisory Committee will review the new drug application for the pain drug Entereg [1] on Jan. 23. Report [2]

> Backed by a fresh batch of positive, mid-stage data for its experimental therapy to treat a rare hormone condition, Indevus says it will launch Phase III by mid-2008. Release [3]

> Exelixis has earned a $5 million milestone payment from Bristol-Myers Squibb. Report [4]

> Belgium's Galapagos wins up to $2.4 million in upfront fees and research funds in a development deal with Cystic Fibrosis Foundation Therapeutics. Up to $5.7 million in milestones is also on the table. Report [5]

> Protein therapy company Medgenics has raised £3.28 million from a share placing with investors. Report [6]

> AstraZeneca got a bit of a windfall today from the FDA, which granted six extra months of exclusive marketing rights to its Arimidex cancer drug. Report [7]

> New warnings and warning recommendations are flying out of the FDA this week like geese flying south for the winter, partly because of an FDA advisory panel is meeting. Report [8]

> Talk about an outpouring of adverse-event reports. After WFAA-TV in Dallas reported musician Carter Albrecht's violent death [9]--perhaps under the influence of Pfizer's smoking-cessation drug Chantix--more than 5,000 complaints about the med's side effects poured into the FDA. Report [10]

And Finally… Hospital superbugs that can break down antibiotics are so widespread throughout Europe that doctors increasingly have to use the few remaining drugs that they reserve for emergencies. Release [11]